{
    "clinical_study": {
        "@rank": "159705", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes."
            }, 
            {
                "arm_group_label": "Ala-Cpn10", 
                "arm_group_type": "Experimental", 
                "description": "Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range (0.16mg/kg [10mg twice weekly] to 5mg/kg [300mg twice weekly]) administered intravenously by infusion over 60 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the safety, tolerability, and efficacy of\n      4 weeks intravenous treatment with Cpn10 in subjects with mildly active SLE."
        }, 
        "brief_title": "Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With SLE.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Erythematosus, Systemic", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (ALL must be met):\n\n        To be entered on study, subjects must meet the following criteria:\n\n          1. Male or female\n\n          2. Age 18 -  75 years\n\n          3. Patients fulfilling at least 4 criteria for Systemic Lupus Erythematosus (SLE) as\n             defined by the American College of Rheumatology (ACR)\n\n          4. Present with mild active SLE disease\n\n          5. Laboratory values as follows:\n\n             i) ANA titer \u2265 1:160 or positive anti-dsDNA antibodies at any time prior to screening\n\n          6. Not pregnant or breast-feeding\n\n          7. Able to tolerate a stable dose of corticosteroids of \u2264 0.3 mg/kg/day of\n             prednisone or equivalent for the duration of the study\n\n          8. Agreement to use an effective form of contraception for the duration of the study.\n\n          9. Ability to understand and give consent.\n\n         10. Willing to participate and able to comply with the study requirements, procedures and\n             visits.\n\n        Exclusion Criteria (NONE can apply):\n\n          1. Active severe SLE flare with central nervous system (CNS) manifestations, active\n             renal lupus, active pericarditis, active pleuritis, active peritonitis or other SLE\n             manifestations requiring treatment not allowed by the study protocol within 4 weeks\n             of screening\n\n          2. Active lupus nephritis and/or severe renal impairment (estimated or measured\n             glomerular filtration rate (GFR) < 50%)\n\n          3. Pregnancy.\n\n          4. Lack of peripheral venous access.\n\n          5. Significant history of arterial or venous thrombosis (blood clots) within 12 months\n             prior to trial start.\n\n          6. Requirement for a stable dose of corticosteroid \u2265 greater than 0.3 mg/kg/day of\n             prednisone or equivalent.\n\n          7. Any therapy with human or murine antibodies.\n\n          8. Any experimental therapy within 3 months.\n\n          9. Therapy with cyclophosphamide; pulse methylprednisolone or i.v. Ig within 4-6 weeks.\n\n         10. Subjects with any the following laboratory abnormalities: serum creatinine >3.0\n             mg/dL, white blood cells (WBC) <3,500/\u03bcL, absolute neutrophil count (ANC) <3,000/\u03bcL,\n             absolute lymphocyte count \u2264500/\u03bcL, Hgb <8.0 g/dL, platelets <50,000/\u03bcL, alanine\n             aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 x upper limit of\n             normal (ULN), alkaline phosphatase >1.5 ULN,\n\n         11. Personal or psychiatric condition that precludes the subject being able to comply\n             with the study requirements or unable to undergo informed consent process.\n\n         12. History of severe systemic bacterial, fungal, viral, or parasitic infections. Have\n             required management or hospitalization of any infection within the last 4 weeks\n             before screening.\n\n         13. History of malignancy - except completely excised basal cell carcinoma.\n\n         14. Impaired hepatic function\n\n         15. Body weight of 260lbs/120kg or more (BMI > 35)\n\n         16. Tuberculosis (TB) or active treatment for TB\n\n         17. History of alcohol or substance abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838694", 
            "org_study_id": "IVXCpn001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ala-Cpn10", 
                "intervention_name": "Ala-Cpn10", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "email": "traceymadonna1125@yahoo.com", 
                "last_name": "Tracey Madonna", 
                "phone": "814-693-0300"
            }, 
            "facility": {
                "address": {
                    "city": "Altoona", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "16635"
                }, 
                "name": "Altoona Arthritis and Osteoporosis Center"
            }, 
            "investigator": {
                "last_name": "Alan Kivitz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reduction from baseline serum Interleukin 6 (IL-6) levels at the end of active dosing, comparing treatment to placebo cohort.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Invion, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Invion, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}